Treatment Pipeline
Hair Loss Treatment Pipeline 2026
New treatments in clinical trials right now. Here's what's coming — and what works today.
Last updated: March 2026
A note on pipeline drugs: Being in Phase 2 or Phase 3 does not mean a drug will reach the market. Many promising clinical candidates fail due to safety issues, insufficient efficacy, or commercial decisions. These are treatments to watch — not treatments to wait for. If you have hair loss now, there are FDA-approved options that work.
In Clinical Trials
Clascoterone 5% (Breezula)
Cassiopea
Topical androgen receptor blocker — blocks DHT at the follicle without systemic effects. First new mechanism for pattern hair loss in 30 years. Unlike finasteride, which reduces DHT throughout the body, clascoterone acts only where it's applied, potentially eliminating the systemic side effects.
PP405
Pelage Pharmaceuticals
Regenerative therapy targeting hair follicle stem cells. Takes a fundamentally different approach from current treatments — instead of blocking androgens or improving blood flow, PP405 reactivates the stem cells that create new hair follicles. If it works as hoped, it could restore hair in areas where current treatments cannot.
Rezpegaldesleukin (LY3471851)
Nektar / Eli Lilly
IL-2 pathway therapy that expands regulatory T cells. Designed for alopecia areata (autoimmune hair loss), not pattern baldness. In alopecia areata, the immune system attacks hair follicles — this drug retrains it. Phase 2 data showed approximately 2x improvement versus placebo on the SALT score (a standardized hair loss severity measure).
All phase data and timeline estimates are sourced from ClinicalTrials.gov, company press releases, and peer-reviewed publications as of March 2026. Clinical timelines regularly shift. FDA approval requires successful Phase 3 completion and regulatory review.
What Works Today
While the pipeline develops, these FDA-approved treatments have decades of evidence behind them.